Patents by Inventor Ching-Shih Chen

Ching-Shih Chen has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA
    Publication number: 20240285556
    Abstract: In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
    Type: Application
    Filed: March 25, 2024
    Publication date: August 29, 2024
    Inventors: Ching-Shih Chen, Christopher C. Coss, Samuel Kulp, Yu-Chou Tseng, Tanios Bekaii-Saab
  • Methods and compositions for the treatment of cancer cachexia
    Patent number: 11938105
    Abstract: In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
    Type: Grant
    Filed: December 19, 2022
    Date of Patent: March 26, 2024
    Assignee: Ohio State Innovation Foundation
    Inventors: Ching-Shih Chen, Christopher C. Coss, Samuel Kulp, Yu-Chou Tseng, Tanios Bekaii-Saab
  • TRADITIONAL CHINESE MEDICINE-BASED AGENT FOR CACHEXIA PREVENTION AND TREATMENT
    Publication number: 20230120360
    Abstract: This invention discloses a traditional Chinese medicine, Mu Dan Pi (Moutan radicis cort), that has the potential to be used for the prevention or treatment of cachexia and muscle loss in cancer patients. The composition is a novel therapeutic agent for cachexia.
    Type: Application
    Filed: October 13, 2022
    Publication date: April 20, 2023
    Applicant: CHINA MEDICAL UNIVERSITY
    Inventors: Hsiang-Wen Lin, Chih-Hsueh Lin, Liang-Yo Yang, Chih-Shiang Chang, Ching-Shih Chen
  • Methods and compositions for the treatment of cancer cachexia
    Patent number: 11529323
    Abstract: In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
    Type: Grant
    Filed: September 13, 2018
    Date of Patent: December 20, 2022
    Assignee: Ohio State Innovation Foundation
    Inventors: Ching-Shih Chen, Christopher C. Coss, Samuel Kulp, Yu-Chou Tseng, Tanios Bekaii-Saab
  • Methods for suppressing cancer-related cachexia
    Patent number: 11219607
    Abstract: Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.
    Type: Grant
    Filed: November 19, 2014
    Date of Patent: January 11, 2022
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Ching-Shih Chen, Tanios Bekaii-Saab, Denis Guttridge, Guido Marcucci, Samuel Kulp, Yu-Chou Tseng
  • Irreversible inhibitors of pyruvate kinase M2 and the use thereof
    Patent number: 11117888
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Grant
    Filed: January 22, 2020
    Date of Patent: September 14, 2021
    Assignee: CHINA MEDICAL UNIVERSITY
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • Irreversible inhibitors of pyruvate kinase M2 and the use thereof
    Publication number: 20210221801
    Abstract: The invention provides a novel class of propiolylamide-based irreversible inhibitors of PKM2 compounds of the general formula I, pharmaceutical compositions, and methods of inducing an anti-tumor effect in a subject suffering from tumor comprising administering to the subject a pharmaceutical composition comprising an effective amount of compound of formula I.
    Type: Application
    Filed: January 22, 2020
    Publication date: July 22, 2021
    Applicant: China Medical University
    Inventors: Ching-Shih Chen, Hsiang-Wen Lin, Chih-Shiang Chang, Po-Chen Chu
  • DERIVATIVES OF PAPAVERINE THAT ARE EFFECTIVE HYPOXIC TUMOR RADIOSENSITIZERS
    Publication number: 20210163453
    Abstract: Disclosed herein are compounds, compositions, and methods for inhibiting mitochondrial oxygen consumption in a cancerous tissue. The compounds, compositions, and methods can be used to treat a subject with hypoxic cancerous tissue.
    Type: Application
    Filed: July 23, 2019
    Publication date: June 3, 2021
    Inventors: Nicholas DENKO, Ioanna PAPANDREOU, Martin BENEJ, Ching-Shih CHEN, Sandip VIBHUTE
  • METHODS AND COMPOSITIONS FOR THE TREATMENT OF CANCER CACHEXIA
    Publication number: 20200289438
    Abstract: In one aspect, the disclosure relates to methods and compositions for treatment of cancer cachexia. In a further aspect, the composition is a pharmaceutical composition comprising a class I/IIB HDAC inhibitor and an androgen. In a still further aspect, the method of treatment comprises administering a class I/IIB HDAC inhibitor and an androgen to a subject or patient who has been diagnosed as having cancer cachexia. In some aspects, the class I/IIB HDAC inhibitor is a compound known as AR-42.
    Type: Application
    Filed: September 13, 2018
    Publication date: September 17, 2020
    Inventors: Ching-Shih Chen, Christopher C. Coss, Samuel Kulp, Yu-Chou Tseng, Tanios Bekaii-Saab
  • Indolyl or indolinyl hydroxamate compounds
    Patent number: 9598364
    Abstract: Indolyl or indolinyl compounds of formula (I): wherein bond, n, R1, R2, R3, R4, R5, and R6, are defined herein. Also disclosed is a method for treating cancer with these compounds.
    Type: Grant
    Filed: August 26, 2014
    Date of Patent: March 21, 2017
    Assignees: Taipei Medical University, Ohio State University, National Taiwan University
    Inventors: Ching-Shih Chen, Jing-Ping Liou, Hsing-Jin Liu, Kuo-Sheng Hung, Pei-Wen Shan, Wen-Ta Chiu, Che-Ming Teng
  • Antibacterial protein kinase inhibitors
    Patent number: 9457031
    Abstract: Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as Myocobacteria tuberculosis.
    Type: Grant
    Filed: July 30, 2013
    Date of Patent: October 4, 2016
    Inventors: Ching-Shih Chen, Santosh Salunke, Larry Schlesinger, Abul K. Azad
  • Glucose transporter inhibitors
    Patent number: 9174951
    Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.
    Type: Grant
    Filed: March 28, 2013
    Date of Patent: November 3, 2015
    Assignee: OHIO STATE INNOVATION FOUNDATION
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • Anticancer P21-activated kinase inhibitors
    Patent number: 9156790
    Abstract: Compounds according to formula I: wherein Ar is a fused aryl group, R1 is selected from alkyl and aryl amides, CF3, and CH2OH, and R2 is selected from hydrogen, —C(?O)CH2NH2, and —C(?O)CH2CH2NH2 are described. The compounds are effective for inhibiting p21-activated kinases, and can be used for prevention and treatment of cancer.
    Type: Grant
    Filed: March 31, 2014
    Date of Patent: October 13, 2015
    Assignee: Ohio State Innovation Foundation
    Inventors: Ching-Shih Chen, Matthew David Ringel, Motoyashi Saji, Yihui Ma
  • ANTIBACTERIAL PROTEIN KINASE INHIBITORS
    Publication number: 20150258100
    Abstract: Methods of treating bacterial infection by in a subject by administering a pharmaceutical composition including a celecoxib derivative are described. The compounds are particularly useful for treating infection by bacteria capable of growing inside macrophages, such as Myocobacteria tuberculosis.
    Type: Application
    Filed: July 30, 2013
    Publication date: September 17, 2015
    Inventors: Ching-Shih Chen, Santosh Salunke, Larry Schlesinger, Abul K. Azad
  • Zn-chelating motif-tethered short-chain fatty acids as a novel class of histone deacetylase inhibitors
    Patent number: 9115090
    Abstract: Zn2+-chelating motif-tethered fatty acids as histone deacetylase (HDAC) inhibitors. Compounds performed well in in vitro and in vivo tests.
    Type: Grant
    Filed: December 1, 2004
    Date of Patent: August 25, 2015
    Assignee: THE OHIO STATE UNIVERSITY RESEARCH FOUNDATION
    Inventor: Ching-Shih Chen
  • Anti-staphylococcal celecoxib derivatives
    Patent number: 9079899
    Abstract: A method of treating infection by Staphylococcus in a subject by administering a pharmaceutical composition including a celecoxib derivative of formula I or a pharmaceutically acceptable salt thereof is described. The preparation of numerous celecoxib derivatives for testing as potential anti-staphylococcal agents is also described.
    Type: Grant
    Filed: October 31, 2011
    Date of Patent: July 14, 2015
    Assignee: THE OHIO STATE UNIVERSITY
    Inventors: Ching-Shih Chen, Hao-Chieh Chiu, Dasheng Wang, Samuel K. Kulp
  • METHODS FOR SUPPRESSING CANCER-RELATED CACHEXIA
    Publication number: 20150150832
    Abstract: Methods of suppressing cachexia in a mammal with cancer comprising administering HDAC inhibitors are provided. Aspects include methods of administering an HDAC class 1 and 2b inhibitor in an amount effective to substantially maintain the mammal's weight compared to a mammal that does receive the HDAC class 1 and 2b inhibitor.
    Type: Application
    Filed: November 19, 2014
    Publication date: June 4, 2015
    Inventors: Ching-Shih Chen, Tanios Bekaii-Saab, Denis Guttridge, Guido Marcucci, Samuel Kulp, Yu-Chou Tseng
  • GLUCOSE TRANSPORTER INHIBITORS
    Publication number: 20150051255
    Abstract: Thiazolidinedione compounds and pharmaceutically acceptable salts thereof are described. The compounds can be used in methods of treating cancer in a subject by administering to the subject a therapeutically effective amount of the compound. The compounds can also be used in methods of inhibiting glucose uptake in a cell by contacting the cell with the compound.
    Type: Application
    Filed: March 28, 2013
    Publication date: February 19, 2015
    Applicant: The Ohio State University Research Foundation
    Inventors: Ching-Shih Chen, Dasheng Wang, Samuel K. Kulp
  • INDOLYL OR INDOLINYL HYDROXAMATE COMPOUNDS
    Publication number: 20140364477
    Abstract: Indolyl or indolinyl compounds of formula (I): wherein bond, n, R1, R2, R3, R4, R5, and R6, are defined herein. Also disclosed is a method for treating cancer with these compounds.
    Type: Application
    Filed: August 26, 2014
    Publication date: December 11, 2014
    Applicants: Ohio State University, National Taiwan University
    Inventors: Ching-Shih Chen, Jing-Ping Liou, Hsing-Jin Liu, Kuo-Sheng Hung, Pei-Wen Shan, Wen-Ta Chiu, Che-Ming Teng
  • ANTICANCER P21-ACTIVATED KINASE INHIBITORS
    Publication number: 20140323538
    Abstract: Compounds according to formula I: wherein Ar is a fused aryl group, R1 is selected from alkyl and aryl amides, CF3, and CH2OH, and R2 is selected from hydrogen, —C(?O)CH2NH2, and —C(?O)CH2CH2NH2 are described. The compounds are effective for inhibiting p21-activated kinases, and can be used for prevention and treatment of cancer.
    Type: Application
    Filed: March 31, 2014
    Publication date: October 30, 2014
    Applicant: Ohio State Innovation Foundation
    Inventors: Ching-Shih Chen, Matthew David Ringel, Motoyashi Saji, Yihui Ma